Huachao Shenkong Takes Its FUS-Neuro Ultrasound Neural Interface Through Type Testing

In September 2026, FUS-Neuro, a closed-loop ultrasound neural interface for neuromodulation from Chinese company Huachao Shenkong (华超神控), passed type testing for medical devices. On paper, it is just one more entry in the chronicle of China's neurotechnology market. In practice, the company is using the moment to state where it thinks the line between hardware and business lies.

What exactly passed testing

FUS-Neuro belongs to a class of systems that use ultrasound to act on neural structures. The key word is "closed-loop." The system does not simply deliver a preset stimulation pattern. It works in a cycle: it reads the state of the brain, makes a decision and adjusts the stimulation. By definition, this architecture requires algorithms that interpret neural signals in real time.

Type testing confirms that a device meets the established technical requirements. It is a necessary step before clinical trials and further registration. According to the source, FUS-Neuro is now moving on an accelerated timeline into the clinical phase for several indications at once.

Why the company does not call itself a hardware maker

Huachao Shenkong founder Li Xin (李昕) stresses that the company has never defined itself as a "maker of ultrasound neural interfaces." The position is easy to understand. Transducers, electronics and housings get copied and get cheaper. If a competitive advantage rests only on them, it is easy to lose once new players enter the market.

The company is betting on NeuroAI: models that learn from neural data and improve their stimulation strategy as they gain experience. In this logic, the value comes not from the device but from the feedback loop. The more data passes through the system, the more precisely it tunes parameters for a specific patient and indication. That explains the question in the headline of the original article about what barrier exists beyond the hardware.

What we know about FUS-Neuro

• Developer: Huachao Shenkong (华超神控) • Product: FUS-Neuro, a closed-loop ultrasound neuromodulation system with neural interface functions • Status: passed type testing for medical devices in September 2026 • Next stage: clinical trials for several indications • Founder: Li Xin • Strategy: developing NeuroAI and the system's ability to evolve, rather than selling hardware alone

What this means for the market

The neural interface market has long split into companies that implant electrodes and companies that work non-invasively. Focused ultrasound is interesting precisely as the second route: it does not require opening the skull, and with good focusing it can also act on deep brain structures. But non-invasive systems have their own problem: the signal is less clear, and the effect depends heavily on individual differences between people. An adaptive algorithm that tunes itself to each patient is what addresses this problem.

For investors and partners, the takeaway is practical. When evaluating neurotechnology companies, look not only at regulatory milestones such as type testing, but also at how the data loop is built: how much clinical data is collected, how it feeds back into the model, and how much the system actually improves over time. For Huachao Shenkong itself, the next test of this thesis will take place in the clinic. That is where it will become clear whether NeuroAI turns from a marketing frame into a measurable advantage.

For developers of medical AI, this is one more signal: in neural interfaces, competition is shifting from device design to the quality of the learning control loop.